Pfizer-Modena mRNA vaccine anaphylaxis 0.025%…Moderna delta mutation primary vaccination 72%

Photo: Courtesy of Pixar Bay

[농업경제신문 임해정 기자] Most people who are allergic to the primary mRNA COVID-19 vaccine can receive the second dose, a study has found.

A second dose can be safely administered to most people who are allergic to the first dose of Pfizer and Moderna’s mRNA COVID-19 vaccine, according to a new study on the 26th (local time), according to Reuters.

In this study, the rate of allergic reactions to the vaccine was reported to be 2%. The researchers said the most serious type, anaphylaxis, occurs in up to 2.5% of 10,000 vaccinated people, or 0.025%. Anaphylaxis refers to a rapid systemic reaction caused by an antigen-antibody immune response.

They reviewed data from 189 adults who had a first dose response to one of these vaccines, such as flushing, dizziness or vertigo, tingling, tight throat, hives, wheezing, or shortness of breath.

The majority (84%) of these adults received a second dose of the vaccine, and about a third had taken an antihistamine beforehand. All of them tolerated the second dose, including an anaphylactic reaction from the first dose.

Potential allergic symptoms that occur after the second dose are mild and easily controllable, the researchers reported on the 26th.

“In the delta mutation, a complete two-dose vaccine has become much more important, and I think there will be more people who don’t get a second dose because of allergy symptoms,” said Matthew Krenz, Ph.D., from Vanderbilt University.

“Our data suggest that the majority of patients with an immediate and potentially allergic reaction to the mRNA COVID-19 vaccine can tolerate a second dose,” they concluded.

In the United States, delta accounts for about 83% of new infections, and unvaccinated people account for nearly 97% of severe cases. Korea will also surpass 50% this week, the Korea Centers for Disease Control and Prevention said.

According to a study by Canadian and British health authorities, a single dose of Moderna was 72% effective against Delta mutations and Pfizer was 36%. However, when the two doses of Pfizer were inoculated, the protection against the delta mutation increased to 88%.

On the morning of the 27th, Jinwon Life Sciences, a stock related to mRNA (messenger ribonucleic acid), is starting to rise 4.50% from the previous day to 48,800 won, and Nyvek to 40,200 won, up 1.64% from the previous day.

Following this, Samyang Holdings, Pharmicell, and Olyx are on the rise, while Cellumed, Engchem Life Sciences, Lee Yeon Pharm, Ijin, Hanmi Science, ST Pharm, Serin Bio, Aminologics, Green Cross, and Hanmi Pharm are on a downtrend.

If Moderna, an mRNA-based vaccine, N2Tech, Somagen, Abprobio, and Pharmicell are mentioned as related stocks, KPX Life Sciences, Woori Bio, Jeil Pharmaceutical, Shinpoong Pharmaceutical, and Celltrion are cited as Pfizer-related stocks.

[알림] This article is for investment judgment reference only, and we are not responsible for any investment loss based on it.

By Lim Hae-jeong, staff reporter [email protected]


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.